Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon

S. Petta, G Cabibbo, M Barbara, S Attardo, L. Bucci, F Farinati, E.G. Giannini, Francesco Tovoli, F. Ciccarese, G. L. Rapaccini, M. Di Marco, Eugenio Caturelli, M. Zoli, F. Borzio, R. Sacco, Roberto Virdone, F. Marra, Martina Felder, F. Morisco, L. BenvegnùA. Gasbarrini, Gianluca Svegliati Baroni, F.G. Foschi, Andrea Olivani, Alberto Masotto, G. Nardone, A. Colecchia, M. Persico, Vincenzo Boccaccio, Antonio Craxì, S. Bruno, F. Trevisani, C. Cammà, the Italian Liver Cancer (ITA.LI.CA) Group, Maurizio Biselli, P. Caraceni, A. Cucchetti, Marco Domenicali, Fabio Piscaglia, A. Gramenzi, Alessandro Granito, Donatella Magalotti, C. Serra, Giulio Negrini, L. Napoli, V. Salvatore, Francesca Benevento, A. Gazzola, Francesca Murer, Caterina Pozzan, V. Vanin, A. Moscatelli, G. Pellegatta, A. Picciotto, V. Savarino, P. DelPoggio, S. Olmi, Nicoletta deMatthaeis, C. Balsamo, E. Vavassori, P. Roselli, S. Dell’Isola, A. M. Ialungo, Elena Rastrelli, F. Rini, A. Costantino, A. Affronti, M. Affronti, M. Mascari, A. Mega, M. Pompili, Emanuele Rinninella, Valeria Mismas, A.C. Dall’Aglio, Valentina Feletti, Arianna Lanzi, Federica Mirici Cappa, E. Neri, G.F. Stefanini, Stefano Tamberi, E. Biasini, G. Missale, M. GUARINO, A. Ortolani, M. Chiaramonte, F. Marchetti, M. Valerio, S. Aburas, A.L. Inghilesi, A. Cappelli, Rita Golfieri, Cristina Mosconi, Matteo Renzulli, P. Coccoli, M.S. Zamparelli, Mariacristina Dimarco

Research output: Contribution to journalArticle

Abstract

Background: In HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma (HCC), the time to HCC recurrence and the effects of sustained viral eradication (SVR) by interferon (IFN)-based or IFN-free regimens on HCC recurrence remain unclear. Aim: To perform an indirect comparison of time to recurrence (TTR) in patients with successfully treated early HCC and active HCV infection with those of patients with SVR by IFN-based and by IFN-free regimens. Methods: We evaluated 443 patients with HCV-related cirrhosis and Barcelona Clinic Liver Cancer Stage A/0 HCC who had a complete radiological response after curative resection or ablation. Active HCV infection was present in 328, selected from the Italian Liver Cancer group cohort; 58 patients had SVR achieved by IFN-free regimens after HCC cure, and 57 patients had SVR achieved by IFN-based regimens after HCC cure. Individual data of patients in the last two groups were extracted from available publications. Results: TTR by Kaplan–Meier curve was significantly lower in patients with active HCV infection compared with those with SVR both by IFN-free (P = 0.02) and by IFN-based (P <0.001) treatments. TTR was similar in patients with SVR by IFN-free or by IFN-based (P = 0.49) strategies. Conclusion: In HCV-infected, successfully treated patients with early HCC, SVR obtained by IFN-based or IFN-free regimens significantly reduce tumour recurrence without differences related to the anti-viral strategy used. © 2016 John Wiley & Sons Ltd
Original languageEnglish
JournalAlimentary Pharmacology and Therapeutics
DOIs
Publication statusE-pub ahead of print - Oct 28 2016

Fingerprint

Interferons
Hepatocellular Carcinoma
Recurrence
Liver Neoplasms
Infection
Nuclear Family
Publications
Fibrosis

Cite this

Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon. / Petta, S.; Cabibbo, G; Barbara, M; Attardo, S; Bucci, L.; Farinati, F; Giannini, E.G.; Tovoli, Francesco; Ciccarese, F.; Rapaccini, G. L.; Di Marco, M.; Caturelli, Eugenio; Zoli, M.; Borzio, F.; Sacco, R.; Virdone, Roberto; Marra, F.; Felder, Martina; Morisco, F.; Benvegnù, L.; Gasbarrini, A.; Svegliati Baroni, Gianluca; Foschi, F.G.; Olivani, Andrea; Masotto, Alberto; Nardone, G.; Colecchia, A.; Persico, M.; Boccaccio, Vincenzo; Craxì, Antonio; Bruno, S.; Trevisani, F.; Cammà, C.; Group, the Italian Liver Cancer (ITA.LI.CA); Biselli, Maurizio; Caraceni, P.; Cucchetti, A.; Domenicali, Marco; Piscaglia, Fabio; Gramenzi, A.; Granito, Alessandro; Magalotti, Donatella; Serra, C.; Negrini, Giulio; Napoli, L.; Salvatore, V.; Benevento, Francesca; Gazzola, A.; Murer, Francesca; Pozzan, Caterina; Vanin, V.; Moscatelli, A.; Pellegatta, G.; Picciotto, A.; Savarino, V.; DelPoggio, P.; Olmi, S.; deMatthaeis, Nicoletta; Balsamo, C.; Vavassori, E.; Roselli, P.; Dell’Isola, S.; Ialungo, A. M.; Rastrelli, Elena; Rini, F.; Costantino, A.; Affronti, A.; Affronti, M.; Mascari, M.; Mega, A.; Pompili, M.; Rinninella, Emanuele; Mismas, Valeria; Dall’Aglio, A.C.; Feletti, Valentina; Lanzi, Arianna; Cappa, Federica Mirici; Neri, E.; Stefanini, G.F.; Tamberi, Stefano; Biasini, E.; Missale, G.; GUARINO, M.; Ortolani, A.; Chiaramonte, M.; Marchetti, F.; Valerio, M.; Aburas, S.; Inghilesi, A.L.; Cappelli, A.; Golfieri, Rita; Mosconi, Cristina; Renzulli, Matteo; Coccoli, P.; Zamparelli, M.S.; Dimarco, Mariacristina.

In: Alimentary Pharmacology and Therapeutics, 28.10.2016.

Research output: Contribution to journalArticle

Petta, S, Cabibbo, G, Barbara, M, Attardo, S, Bucci, L, Farinati, F, Giannini, EG, Tovoli, F, Ciccarese, F, Rapaccini, GL, Di Marco, M, Caturelli, E, Zoli, M, Borzio, F, Sacco, R, Virdone, R, Marra, F, Felder, M, Morisco, F, Benvegnù, L, Gasbarrini, A, Svegliati Baroni, G, Foschi, FG, Olivani, A, Masotto, A, Nardone, G, Colecchia, A, Persico, M, Boccaccio, V, Craxì, A, Bruno, S, Trevisani, F, Cammà, C, Group, TILCITALICA, Biselli, M, Caraceni, P, Cucchetti, A, Domenicali, M, Piscaglia, F, Gramenzi, A, Granito, A, Magalotti, D, Serra, C, Negrini, G, Napoli, L, Salvatore, V, Benevento, F, Gazzola, A, Murer, F, Pozzan, C, Vanin, V, Moscatelli, A, Pellegatta, G, Picciotto, A, Savarino, V, DelPoggio, P, Olmi, S, deMatthaeis, N, Balsamo, C, Vavassori, E, Roselli, P, Dell’Isola, S, Ialungo, AM, Rastrelli, E, Rini, F, Costantino, A, Affronti, A, Affronti, M, Mascari, M, Mega, A, Pompili, M, Rinninella, E, Mismas, V, Dall’Aglio, AC, Feletti, V, Lanzi, A, Cappa, FM, Neri, E, Stefanini, GF, Tamberi, S, Biasini, E, Missale, G, GUARINO, M, Ortolani, A, Chiaramonte, M, Marchetti, F, Valerio, M, Aburas, S, Inghilesi, AL, Cappelli, A, Golfieri, R, Mosconi, C, Renzulli, M, Coccoli, P, Zamparelli, MS & Dimarco, M 2016, 'Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon', Alimentary Pharmacology and Therapeutics. https://doi.org/10.1111/apt.13821
Petta, S. ; Cabibbo, G ; Barbara, M ; Attardo, S ; Bucci, L. ; Farinati, F ; Giannini, E.G. ; Tovoli, Francesco ; Ciccarese, F. ; Rapaccini, G. L. ; Di Marco, M. ; Caturelli, Eugenio ; Zoli, M. ; Borzio, F. ; Sacco, R. ; Virdone, Roberto ; Marra, F. ; Felder, Martina ; Morisco, F. ; Benvegnù, L. ; Gasbarrini, A. ; Svegliati Baroni, Gianluca ; Foschi, F.G. ; Olivani, Andrea ; Masotto, Alberto ; Nardone, G. ; Colecchia, A. ; Persico, M. ; Boccaccio, Vincenzo ; Craxì, Antonio ; Bruno, S. ; Trevisani, F. ; Cammà, C. ; Group, the Italian Liver Cancer (ITA.LI.CA) ; Biselli, Maurizio ; Caraceni, P. ; Cucchetti, A. ; Domenicali, Marco ; Piscaglia, Fabio ; Gramenzi, A. ; Granito, Alessandro ; Magalotti, Donatella ; Serra, C. ; Negrini, Giulio ; Napoli, L. ; Salvatore, V. ; Benevento, Francesca ; Gazzola, A. ; Murer, Francesca ; Pozzan, Caterina ; Vanin, V. ; Moscatelli, A. ; Pellegatta, G. ; Picciotto, A. ; Savarino, V. ; DelPoggio, P. ; Olmi, S. ; deMatthaeis, Nicoletta ; Balsamo, C. ; Vavassori, E. ; Roselli, P. ; Dell’Isola, S. ; Ialungo, A. M. ; Rastrelli, Elena ; Rini, F. ; Costantino, A. ; Affronti, A. ; Affronti, M. ; Mascari, M. ; Mega, A. ; Pompili, M. ; Rinninella, Emanuele ; Mismas, Valeria ; Dall’Aglio, A.C. ; Feletti, Valentina ; Lanzi, Arianna ; Cappa, Federica Mirici ; Neri, E. ; Stefanini, G.F. ; Tamberi, Stefano ; Biasini, E. ; Missale, G. ; GUARINO, M. ; Ortolani, A. ; Chiaramonte, M. ; Marchetti, F. ; Valerio, M. ; Aburas, S. ; Inghilesi, A.L. ; Cappelli, A. ; Golfieri, Rita ; Mosconi, Cristina ; Renzulli, Matteo ; Coccoli, P. ; Zamparelli, M.S. ; Dimarco, Mariacristina. / Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon. In: Alimentary Pharmacology and Therapeutics. 2016.
@article{3822ee0c79b5493f829fe28efcabaacf,
title = "Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon",
abstract = "Background: In HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma (HCC), the time to HCC recurrence and the effects of sustained viral eradication (SVR) by interferon (IFN)-based or IFN-free regimens on HCC recurrence remain unclear. Aim: To perform an indirect comparison of time to recurrence (TTR) in patients with successfully treated early HCC and active HCV infection with those of patients with SVR by IFN-based and by IFN-free regimens. Methods: We evaluated 443 patients with HCV-related cirrhosis and Barcelona Clinic Liver Cancer Stage A/0 HCC who had a complete radiological response after curative resection or ablation. Active HCV infection was present in 328, selected from the Italian Liver Cancer group cohort; 58 patients had SVR achieved by IFN-free regimens after HCC cure, and 57 patients had SVR achieved by IFN-based regimens after HCC cure. Individual data of patients in the last two groups were extracted from available publications. Results: TTR by Kaplan–Meier curve was significantly lower in patients with active HCV infection compared with those with SVR both by IFN-free (P = 0.02) and by IFN-based (P <0.001) treatments. TTR was similar in patients with SVR by IFN-free or by IFN-based (P = 0.49) strategies. Conclusion: In HCV-infected, successfully treated patients with early HCC, SVR obtained by IFN-based or IFN-free regimens significantly reduce tumour recurrence without differences related to the anti-viral strategy used. {\circledC} 2016 John Wiley & Sons Ltd",
author = "S. Petta and G Cabibbo and M Barbara and S Attardo and L. Bucci and F Farinati and E.G. Giannini and Francesco Tovoli and F. Ciccarese and Rapaccini, {G. L.} and {Di Marco}, M. and Eugenio Caturelli and M. Zoli and F. Borzio and R. Sacco and Roberto Virdone and F. Marra and Martina Felder and F. Morisco and L. Benvegn{\`u} and A. Gasbarrini and {Svegliati Baroni}, Gianluca and F.G. Foschi and Andrea Olivani and Alberto Masotto and G. Nardone and A. Colecchia and M. Persico and Vincenzo Boccaccio and Antonio Crax{\`i} and S. Bruno and F. Trevisani and C. Camm{\`a} and Group, {the Italian Liver Cancer (ITA.LI.CA)} and Maurizio Biselli and P. Caraceni and A. Cucchetti and Marco Domenicali and Fabio Piscaglia and A. Gramenzi and Alessandro Granito and Donatella Magalotti and C. Serra and Giulio Negrini and L. Napoli and V. Salvatore and Francesca Benevento and A. Gazzola and Francesca Murer and Caterina Pozzan and V. Vanin and A. Moscatelli and G. Pellegatta and A. Picciotto and V. Savarino and P. DelPoggio and S. Olmi and Nicoletta deMatthaeis and C. Balsamo and E. Vavassori and P. Roselli and S. Dell’Isola and Ialungo, {A. M.} and Elena Rastrelli and F. Rini and A. Costantino and A. Affronti and M. Affronti and M. Mascari and A. Mega and M. Pompili and Emanuele Rinninella and Valeria Mismas and A.C. Dall’Aglio and Valentina Feletti and Arianna Lanzi and Cappa, {Federica Mirici} and E. Neri and G.F. Stefanini and Stefano Tamberi and E. Biasini and G. Missale and M. GUARINO and A. Ortolani and M. Chiaramonte and F. Marchetti and M. Valerio and S. Aburas and A.L. Inghilesi and A. Cappelli and Rita Golfieri and Cristina Mosconi and Matteo Renzulli and P. Coccoli and M.S. Zamparelli and Mariacristina Dimarco",
note = "Cited By :1 Export Date: 21 March 2017 CODEN: APTHE Correspondence Address: Camm{\`a}, C.Italy; email: calogero.camma@unipa.it References: Ferlay, J., Shin, H.R., Bray, F., Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 (2010) Int J Cancer, 127, pp. 2893-2917; Alazawi, W., Cunningham, M., Dearden, J., Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection (2010) Aliment Pharmacol Ther, 32, pp. 344-355; Bucci, L., Garuti, F., Camelli, V., Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatment and outcome (2016) Aliment Pharmacol Ther, 43, pp. 385-399; EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma (2012) J Hepatol, 56, pp. 908-943; Bruix, J., Reig, M., Sherman, M., Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma (2016) Gastroenterology, 150, pp. 835-853; 2014 KLCSG-NCC Korea practice guideline for the management of hepatocellular carcinoma (2015) Gut Liv, 9, pp. 267-317; Mazzaferro, V., Lencioni, R., Majno, P., Early hepatocellular carcinoma on the procrustean bed of ablation, resection, and transplantation (2014) Semin Liver Dis, 34, pp. 415-426; Llovet, J.M., Di Bisceglie, A.M., Bruix, J., Design and endpoints of clinical trials in hepatocellular carcinoma (2008) J Natl Cancer Inst, 100, pp. 698-711; Cabibbo, G., Reig, M., Gadaleta-Caldarola, G., The calm before the storm: a report from the International Liver Cancer Association Congress 2015 - part 2 (2016) Future Oncol, 12, pp. 285-288; Bruix, J., Takayama, T., Mazzaferro, V., Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial (2015) Lancet Oncol, 16, pp. 1344-1354; Di Marco, V., Calvaruso, V., Ferraro, D., Effects of viral eradication in patients with hepatitis C virus and cirrhosis differ with stage of portal hypertension (2016) Gastroenterology, 151, pp. 130-139; Petta, S., Di Marco, V., Bruno, S., Impact of virus eradication in patients with compensated hepatitis C virus-related cirrhosis: competing risks and multistate model (2016) Liver Int, , [Epub ahead of print]; Miyake, Y., Takaki, A., Iwasaki, Y., Yamamoto, K., Meta-analysis: interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma (2010) J Viral Hepat, 17, pp. 287-292; Singal, A.K., Freeman, D.H., Jr., Anand, B.S., Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma (2010) Aliment Pharmacol Ther, 32, pp. 851-858; Miao, R.Y., Zhao, H.T., Yang, H.Y., Postoperative adjuvant antiviral therapy for hepatitis B/C virus-related hepatocellular carcinoma: a meta-analysis (2010) World J Gastroenterol, 16, pp. 2931-2942; Zhuang, L., Zeng, X., Yang, Z., Meng, Z., Effect and safety of interferon for hepatocellular carcinoma: a systematic review and meta-analysis (2013) PLoS ONE, 8; Zhang, W., Song, T.Q., Zhang, T., Adjuvant interferon for early or late recurrence of hepatocellular carcinoma and mortality from hepatocellular carcinoma following curative treatment: a meta-analysis with comparison of different types of hepatitis (2014) Mol Clin Oncol, 2, pp. 1125-1134; Reig, M., Mari{\~n}o, Z., Perell{\'o}, C., Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution (2016) J Hepatol, 65, pp. 719-726; Conti, F., Buonfiglioli, F., Scuteri, A., Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals (2016) J Hepatol, 65, pp. 727-733; Pugh, R.N., Murray-Lyon, I.M., Dawson, J.L., Transection of the oesophagus for bleeding oesophageal varices (1973) Br J Surg, 60, pp. 646-649; Malinchoc, M., Kamath, P.S., Gordon, F.D., A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts (2000) Hepatology, 31, pp. 864-871; Garcia-Tsao, G., Sanyal, A.J., Grace, N.D., Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis (2007) Hepatology, 46, pp. 922-938; Oken, M.M., Creech, R.H., Tormey, D.C., Toxicity and response criteria of the Eastern Cooperative Oncology Group (1982) Am J Clin Oncol, 5, pp. 649-655; Mazzaferro, V., Regalia, E., Doci, R., Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis (1996) N Engl J Med, 334, pp. 693-699; Suou, T., Mitsuda, A., Koda, M., Interferon alpha inhibits intrahepatic recurrence in hepatocellular carcinoma with chronic hepatitis C: a pilot study (2001) Hepatol Res, 20, pp. 301-311; Jeong, S.C., Aikata, H., Katamura, Y., Effects of a 24-week course of interferon-alpha therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma (2007) World J Gastroenterol, 13, pp. 5343-5350; Kanogawa, N., Ogasawara, S., Chiba, T., Sustained virologic response achieved after curative treatment of hepatitis C virus-related hepatocellular carcinoma as an independent prognostic factor (2015) J Gastroenterol Hepatol, 30, pp. 1197-1204; Camm{\`a}, C., Cabibbo, G., Crax{\`i}, A., Direct antiviral agents and risk for hepatocellular carcinoma early recurrence: much ado about nothing (2016) J Hepatol, 65, pp. 861-862; Rohatgi, A., WebPlotDigitizer, , http://arohatgi.info/WebPlotDigitizer, (accessed May 2016); Giannini, E.G., Sammito, G., Farinati, F., Determinants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: implications for its clinical use (2014) Cancer, 120, pp. 2150-2157; Tatsumi, T., Takehara, T., Impact of NK cells on chronic hepatitis C and hepatocellular carcinoma (2016) Hepatol Res, 46, pp. 416-422; Brownell, J., Polyak, S.J., Molecular pathways: hepatitis C virus, CXCL10, and the inflammatory road to liver cancer (2013) Clin Cancer Res, 19, pp. 1347-1352",
year = "2016",
month = "10",
day = "28",
doi = "10.1111/apt.13821",
language = "English",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell Publishing Ltd",

}

TY - JOUR

T1 - Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon

AU - Petta, S.

AU - Cabibbo, G

AU - Barbara, M

AU - Attardo, S

AU - Bucci, L.

AU - Farinati, F

AU - Giannini, E.G.

AU - Tovoli, Francesco

AU - Ciccarese, F.

AU - Rapaccini, G. L.

AU - Di Marco, M.

AU - Caturelli, Eugenio

AU - Zoli, M.

AU - Borzio, F.

AU - Sacco, R.

AU - Virdone, Roberto

AU - Marra, F.

AU - Felder, Martina

AU - Morisco, F.

AU - Benvegnù, L.

AU - Gasbarrini, A.

AU - Svegliati Baroni, Gianluca

AU - Foschi, F.G.

AU - Olivani, Andrea

AU - Masotto, Alberto

AU - Nardone, G.

AU - Colecchia, A.

AU - Persico, M.

AU - Boccaccio, Vincenzo

AU - Craxì, Antonio

AU - Bruno, S.

AU - Trevisani, F.

AU - Cammà, C.

AU - Group, the Italian Liver Cancer (ITA.LI.CA)

AU - Biselli, Maurizio

AU - Caraceni, P.

AU - Cucchetti, A.

AU - Domenicali, Marco

AU - Piscaglia, Fabio

AU - Gramenzi, A.

AU - Granito, Alessandro

AU - Magalotti, Donatella

AU - Serra, C.

AU - Negrini, Giulio

AU - Napoli, L.

AU - Salvatore, V.

AU - Benevento, Francesca

AU - Gazzola, A.

AU - Murer, Francesca

AU - Pozzan, Caterina

AU - Vanin, V.

AU - Moscatelli, A.

AU - Pellegatta, G.

AU - Picciotto, A.

AU - Savarino, V.

AU - DelPoggio, P.

AU - Olmi, S.

AU - deMatthaeis, Nicoletta

AU - Balsamo, C.

AU - Vavassori, E.

AU - Roselli, P.

AU - Dell’Isola, S.

AU - Ialungo, A. M.

AU - Rastrelli, Elena

AU - Rini, F.

AU - Costantino, A.

AU - Affronti, A.

AU - Affronti, M.

AU - Mascari, M.

AU - Mega, A.

AU - Pompili, M.

AU - Rinninella, Emanuele

AU - Mismas, Valeria

AU - Dall’Aglio, A.C.

AU - Feletti, Valentina

AU - Lanzi, Arianna

AU - Cappa, Federica Mirici

AU - Neri, E.

AU - Stefanini, G.F.

AU - Tamberi, Stefano

AU - Biasini, E.

AU - Missale, G.

AU - GUARINO, M.

AU - Ortolani, A.

AU - Chiaramonte, M.

AU - Marchetti, F.

AU - Valerio, M.

AU - Aburas, S.

AU - Inghilesi, A.L.

AU - Cappelli, A.

AU - Golfieri, Rita

AU - Mosconi, Cristina

AU - Renzulli, Matteo

AU - Coccoli, P.

AU - Zamparelli, M.S.

AU - Dimarco, Mariacristina

N1 - Cited By :1 Export Date: 21 March 2017 CODEN: APTHE Correspondence Address: Cammà, C.Italy; email: calogero.camma@unipa.it References: Ferlay, J., Shin, H.R., Bray, F., Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 (2010) Int J Cancer, 127, pp. 2893-2917; Alazawi, W., Cunningham, M., Dearden, J., Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection (2010) Aliment Pharmacol Ther, 32, pp. 344-355; Bucci, L., Garuti, F., Camelli, V., Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatment and outcome (2016) Aliment Pharmacol Ther, 43, pp. 385-399; EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma (2012) J Hepatol, 56, pp. 908-943; Bruix, J., Reig, M., Sherman, M., Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma (2016) Gastroenterology, 150, pp. 835-853; 2014 KLCSG-NCC Korea practice guideline for the management of hepatocellular carcinoma (2015) Gut Liv, 9, pp. 267-317; Mazzaferro, V., Lencioni, R., Majno, P., Early hepatocellular carcinoma on the procrustean bed of ablation, resection, and transplantation (2014) Semin Liver Dis, 34, pp. 415-426; Llovet, J.M., Di Bisceglie, A.M., Bruix, J., Design and endpoints of clinical trials in hepatocellular carcinoma (2008) J Natl Cancer Inst, 100, pp. 698-711; Cabibbo, G., Reig, M., Gadaleta-Caldarola, G., The calm before the storm: a report from the International Liver Cancer Association Congress 2015 - part 2 (2016) Future Oncol, 12, pp. 285-288; Bruix, J., Takayama, T., Mazzaferro, V., Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial (2015) Lancet Oncol, 16, pp. 1344-1354; Di Marco, V., Calvaruso, V., Ferraro, D., Effects of viral eradication in patients with hepatitis C virus and cirrhosis differ with stage of portal hypertension (2016) Gastroenterology, 151, pp. 130-139; Petta, S., Di Marco, V., Bruno, S., Impact of virus eradication in patients with compensated hepatitis C virus-related cirrhosis: competing risks and multistate model (2016) Liver Int, , [Epub ahead of print]; Miyake, Y., Takaki, A., Iwasaki, Y., Yamamoto, K., Meta-analysis: interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma (2010) J Viral Hepat, 17, pp. 287-292; Singal, A.K., Freeman, D.H., Jr., Anand, B.S., Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma (2010) Aliment Pharmacol Ther, 32, pp. 851-858; Miao, R.Y., Zhao, H.T., Yang, H.Y., Postoperative adjuvant antiviral therapy for hepatitis B/C virus-related hepatocellular carcinoma: a meta-analysis (2010) World J Gastroenterol, 16, pp. 2931-2942; Zhuang, L., Zeng, X., Yang, Z., Meng, Z., Effect and safety of interferon for hepatocellular carcinoma: a systematic review and meta-analysis (2013) PLoS ONE, 8; Zhang, W., Song, T.Q., Zhang, T., Adjuvant interferon for early or late recurrence of hepatocellular carcinoma and mortality from hepatocellular carcinoma following curative treatment: a meta-analysis with comparison of different types of hepatitis (2014) Mol Clin Oncol, 2, pp. 1125-1134; Reig, M., Mariño, Z., Perelló, C., Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution (2016) J Hepatol, 65, pp. 719-726; Conti, F., Buonfiglioli, F., Scuteri, A., Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals (2016) J Hepatol, 65, pp. 727-733; Pugh, R.N., Murray-Lyon, I.M., Dawson, J.L., Transection of the oesophagus for bleeding oesophageal varices (1973) Br J Surg, 60, pp. 646-649; Malinchoc, M., Kamath, P.S., Gordon, F.D., A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts (2000) Hepatology, 31, pp. 864-871; Garcia-Tsao, G., Sanyal, A.J., Grace, N.D., Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis (2007) Hepatology, 46, pp. 922-938; Oken, M.M., Creech, R.H., Tormey, D.C., Toxicity and response criteria of the Eastern Cooperative Oncology Group (1982) Am J Clin Oncol, 5, pp. 649-655; Mazzaferro, V., Regalia, E., Doci, R., Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis (1996) N Engl J Med, 334, pp. 693-699; Suou, T., Mitsuda, A., Koda, M., Interferon alpha inhibits intrahepatic recurrence in hepatocellular carcinoma with chronic hepatitis C: a pilot study (2001) Hepatol Res, 20, pp. 301-311; Jeong, S.C., Aikata, H., Katamura, Y., Effects of a 24-week course of interferon-alpha therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma (2007) World J Gastroenterol, 13, pp. 5343-5350; Kanogawa, N., Ogasawara, S., Chiba, T., Sustained virologic response achieved after curative treatment of hepatitis C virus-related hepatocellular carcinoma as an independent prognostic factor (2015) J Gastroenterol Hepatol, 30, pp. 1197-1204; Cammà, C., Cabibbo, G., Craxì, A., Direct antiviral agents and risk for hepatocellular carcinoma early recurrence: much ado about nothing (2016) J Hepatol, 65, pp. 861-862; Rohatgi, A., WebPlotDigitizer, , http://arohatgi.info/WebPlotDigitizer, (accessed May 2016); Giannini, E.G., Sammito, G., Farinati, F., Determinants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: implications for its clinical use (2014) Cancer, 120, pp. 2150-2157; Tatsumi, T., Takehara, T., Impact of NK cells on chronic hepatitis C and hepatocellular carcinoma (2016) Hepatol Res, 46, pp. 416-422; Brownell, J., Polyak, S.J., Molecular pathways: hepatitis C virus, CXCL10, and the inflammatory road to liver cancer (2013) Clin Cancer Res, 19, pp. 1347-1352

PY - 2016/10/28

Y1 - 2016/10/28

N2 - Background: In HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma (HCC), the time to HCC recurrence and the effects of sustained viral eradication (SVR) by interferon (IFN)-based or IFN-free regimens on HCC recurrence remain unclear. Aim: To perform an indirect comparison of time to recurrence (TTR) in patients with successfully treated early HCC and active HCV infection with those of patients with SVR by IFN-based and by IFN-free regimens. Methods: We evaluated 443 patients with HCV-related cirrhosis and Barcelona Clinic Liver Cancer Stage A/0 HCC who had a complete radiological response after curative resection or ablation. Active HCV infection was present in 328, selected from the Italian Liver Cancer group cohort; 58 patients had SVR achieved by IFN-free regimens after HCC cure, and 57 patients had SVR achieved by IFN-based regimens after HCC cure. Individual data of patients in the last two groups were extracted from available publications. Results: TTR by Kaplan–Meier curve was significantly lower in patients with active HCV infection compared with those with SVR both by IFN-free (P = 0.02) and by IFN-based (P <0.001) treatments. TTR was similar in patients with SVR by IFN-free or by IFN-based (P = 0.49) strategies. Conclusion: In HCV-infected, successfully treated patients with early HCC, SVR obtained by IFN-based or IFN-free regimens significantly reduce tumour recurrence without differences related to the anti-viral strategy used. © 2016 John Wiley & Sons Ltd

AB - Background: In HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma (HCC), the time to HCC recurrence and the effects of sustained viral eradication (SVR) by interferon (IFN)-based or IFN-free regimens on HCC recurrence remain unclear. Aim: To perform an indirect comparison of time to recurrence (TTR) in patients with successfully treated early HCC and active HCV infection with those of patients with SVR by IFN-based and by IFN-free regimens. Methods: We evaluated 443 patients with HCV-related cirrhosis and Barcelona Clinic Liver Cancer Stage A/0 HCC who had a complete radiological response after curative resection or ablation. Active HCV infection was present in 328, selected from the Italian Liver Cancer group cohort; 58 patients had SVR achieved by IFN-free regimens after HCC cure, and 57 patients had SVR achieved by IFN-based regimens after HCC cure. Individual data of patients in the last two groups were extracted from available publications. Results: TTR by Kaplan–Meier curve was significantly lower in patients with active HCV infection compared with those with SVR both by IFN-free (P = 0.02) and by IFN-based (P <0.001) treatments. TTR was similar in patients with SVR by IFN-free or by IFN-based (P = 0.49) strategies. Conclusion: In HCV-infected, successfully treated patients with early HCC, SVR obtained by IFN-based or IFN-free regimens significantly reduce tumour recurrence without differences related to the anti-viral strategy used. © 2016 John Wiley & Sons Ltd

U2 - 10.1111/apt.13821

DO - 10.1111/apt.13821

M3 - Article

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

ER -